4/22
04:34 pm
vygr
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting [Yahoo! Finance]
Low
Report
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting [Yahoo! Finance]
4/22
04:30 pm
vygr
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Low
Report
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
4/16
07:00 am
vygr
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Low
Report
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
4/15
09:14 am
vygr
NorthStar Appoints Peter Pfreundschuh to Board of Managers [Yahoo! Finance]
Low
Report
NorthStar Appoints Peter Pfreundschuh to Board of Managers [Yahoo! Finance]
4/15
09:00 am
vygr
NorthStar Appoints Peter Pfreundschuh to Board of Managers
Low
Report
NorthStar Appoints Peter Pfreundschuh to Board of Managers
4/9
03:06 pm
vygr
Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? [Yahoo! Finance]
Low
Report
Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? [Yahoo! Finance]
3/26
04:18 pm
vygr
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/26
04:01 pm
vygr
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/26
08:12 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is now covered by analysts at Guggenheim. They set a "buy" rating and a $22.00 price target on the stock.
Medium
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is now covered by analysts at Guggenheim. They set a "buy" rating and a $22.00 price target on the stock.
3/19
08:08 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Medium
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
3/13
01:34 pm
vygr
Voyager Therapeutics: On Track To Deliver High Returns On Investment [Seeking Alpha]
Low
Report
Voyager Therapeutics: On Track To Deliver High Returns On Investment [Seeking Alpha]
3/13
07:16 am
vygr
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer [Yahoo! Finance]
3/13
07:00 am
vygr
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
Medium
Report
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
3/9
02:09 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/8
03:47 pm
vygr
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier [Seeking Alpha]
Low
Report
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier [Seeking Alpha]
3/7
08:02 am
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $16.00 price target on the stock.
Low
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $16.00 price target on the stock.
3/4
05:53 am
vygr
Analysts Just Made A Major Revision To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Forecasts [Yahoo! Finance]
Medium
Report
Analysts Just Made A Major Revision To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Forecasts [Yahoo! Finance]
2/29
11:05 pm
vygr
Voyager Therapeutics, Inc. (NASDAQ: VYGR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
High
Report
Voyager Therapeutics, Inc. (NASDAQ: VYGR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
2/29
10:12 am
vygr
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
04:53 pm
vygr
Voyager Therapeutics Inc (VYGR) Announces Strong Year-End Financials with Significant Cash Position [Yahoo! Finance]
High
Report
Voyager Therapeutics Inc (VYGR) Announces Strong Year-End Financials with Significant Cash Position [Yahoo! Finance]
2/28
04:13 pm
vygr
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results [Yahoo! Finance]
High
Report
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results [Yahoo! Finance]
2/28
04:01 pm
vygr
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Medium
Report
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2/26
07:00 am
vygr
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Low
Report
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
2/21
07:00 am
vygr
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
Low
Report
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
2/20
07:08 am
vygr
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research [Yahoo! Finance]
Medium
Report
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research [Yahoo! Finance]